Related Experiment Video
Updated: Jun 26, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Orai1/STIMs modulators in pulmonary vascular diseases
Anaïs Saint-Martin Willer1, David Montani2, Véronique Capuano3
1Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999 Hypertension pulmonaire: Physiopathologie et Innovation Thérapeutique, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
Calcium (Ca2+) channels, like Orai1, are vital for cellular processes. This review explores Orai1
Area of Science:
- Cellular Biology
- Physiology
- Pathology
Background:
- Calcium ions (Ca2+) act as crucial secondary messengers regulating diverse cellular functions.
- Orai1 channels are key players in store-operated calcium entry (SOCE), maintaining cellular Ca2+ homeostasis.
- Orai1 dysregulation is implicated in severe combined immune deficiency, cancers, and cardiorespiratory diseases like pulmonary arterial hypertension (PAH).
Purpose of the Study:
- To review the regulatory partners of Orai1 channels.
- To elucidate the role of these partners in Orai1-mediated SOCE.
- To understand Orai1 dysregulation in pulmonary circulation and inflammation.
Main Methods:
- Literature review of Orai1 regulatory mechanisms.
- Analysis of Orai1 interactions with STIM proteins and other partners.
- Focus on Orai1's role in physiological and pathological conditions of the pulmonary system.
Main Results:
- Orai1 activation is primarily modulated by STIM proteins, particularly STIM1.
- Numerous other regulatory partners of Orai1 have been identified recently.
- These partners offer insights into SOCE signaling pathways and Orai1's role in disease.
Conclusions:
- Understanding Orai1 regulatory partners enhances our view of SOCE signaling.
- Identifying these partners provides therapeutic targets for Orai1-related diseases.
- Further research into Orai1 partners is crucial for treating pulmonary and inflammatory conditions.
More Related Videos
07:41A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
Published on: March 1, 2022
10:20Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
Published on: January 16, 2013
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...